2012
Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socié G, Méchinaud F, Doz F, Neven B, Bertrand Y, Galambrun C, Demeocq F, Yakouben K, Bordigoni P, Frappaz D, Nguyen L, Vassal G.
Pediatr Blood Cancer. 2012 Jan;58(1):90-7. doi: 10.1002/pbc.22959. Epub 2011 Jan 19.
Doussau A, Asselain B, Le Deley MC, Geoerger B, Doz F, Vassal G, Paoletti X.
Contemp Clin Trials. 2012 Jul;33(4):657-65. Epub 2012 Apr 13.
2010
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.
Br J Haematol. 2010 Mar;148(5):768-76. Epub 2009 Dec 8.
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8.
2008
Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY.
Blood. 2008 Aug 15;112(4):1005-12. Epub 2008 May 13.
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Cancer Chemother Pharmacol. 2008 Jan;61(1):113-23. Epub 2007 Mar 29.